Study to Assess to Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole

Phase: 2/3

Status: Ongoing

Details

MACrO2 – A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Prospective Study to Assess to Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients with treatment-Refractory Mycobacterium avium Complex Lung Disease – Protocol EBO-301

Sponsor: AN2 Therapeutics

IRB#: 2022-029

Sponsors

HOPE Cancer Center

Hope Cancer Center

Contact

Contact UT Clinical
Scroll to Top